NCT05970510View on ClinicalTrials.gov

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

PHASE3RecruitingINTERVENTIONAL
Enrollment

555

Participants

Timeline

Start Date

July 12, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Generalized Anxiety Disorder
Interventions
DRUG

Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg

orally once a day

DRUG

Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg

orally once a day

DRUG

placebo

orally once a day

Trial Locations (1)

Unknown

RECRUITING

Peking University Sixth Hospital, Beijing

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY